Lupus Nephritis

Patients with systematic lupus erythematosus who have a low platelet distribution width are more likely to have lupus nephritis.

The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin for the treatment of lupus nephritis.

Adding belimumab to standard therapy for lupus nephritis is associated with better renal outcomes compared with standard therapy alone.

The NDA for voclosporin has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.

Patients with active lupus nephritis who received voclosporin experienced a superior renal response as patients receiving standard of care.

Researchers examined the burden of renal arteriosclerosis in lupus nephritis (LN), and they also assessed whether arteriosclerosis was underreported in LN biopsies.

A study found that renal arteriosclerosis develops 2 decades earlier in patients with lupus nephritis compared with healthy age-matched controls.

GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.